New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
10:28 EDTVRTX, KPTI, EBKDY, VSTM, ZINC, ZBRA, TFM, HOS, BRKR, BECNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Beacon Roofing (BECN) downgraded to Market Perform from Outperform at William Blair... Bruker (BRKR) downgraded to Neutral from Buy at ISI Group... Erste Group Bank (EBKDY) downgraded to Hold from Buy at Deutsche Bank... Hornbeck Offshore (HOS) downgraded to Equal Weight from Overweight at Stephens... Horsehead Holding (ZINC) downgraded to Market Perform at FBR Capital... Karyopharm (KPTI) downgraded to Perform from Outperform at Oppenheimer... The Fresh Market (TFM) downgraded to Sell from Neutral at Goldman... Verastem (VSTM) downgraded to Perform from Outperform at Oppenheimer... Vertex (VRTX) downgraded to Perform from Outperform at Oppenheimer... Zebra Technologies (ZBRA) downgraded to In-Line from Outperform at Imperial Capital.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 21, 2015
05:48 EDTBRKRBruker downgraded to Market Perform from Outperform at William Blair
Subscribe for More Information
05:31 EDTBRKRBruker downgraded to Neutral from Buy at Mizuho
Subscribe for More Information
May 20, 2015
16:39 EDTBRKRBruker authorizes share repurchase program, amount not specified
In a regulatory filing, Bruker reports that on May 15, its board of directors authorized a share repurchase program pursuant to which the company may repurchase common stock in amounts intended to approximately offset, on an annual basis, the dilutive effect of shares that may be issued pursuant to option awards or restricted stock grants under its compensation plan. It is currently expected that the annual repurchase activity will initially target an amount of shares not to exceed 1% of the total number of shares.
16:20 EDTBRKRBruker CFO Charles Wagner to depart June 12
Subscribe for More Information
May 19, 2015
08:57 EDTKPTILeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
08:50 EDTBRKRBruker has a conference call hosted by JPMorgan
Subscribe for More Information
07:56 EDTVRTXGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:28 EDTBRKRUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
06:22 EDTBECNBeacon Roofing management to meet with William Blair
Subscribe for More Information
May 17, 2015
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
May 15, 2015
09:31 EDTVRTXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 14, 2015
09:11 EDTBRKRBruker secures contract for DE-tector ETD system
Subscribe for More Information
May 13, 2015
19:12 EDTKPTIOn The Fly: After Hours Movers
UP AFTER EARNINGS: Paragon Offshore (PGN), up 10.3%... Shake Shack (SHAK), up 10%... Vipshop Holdings (VIPS), up 6.7%. ALSO HIGHER: Vascular Biogenics (VBLT), up 12.8% and Oncothyreon (ONTY), up 15.5% after release of ASCO presentation data. DOWN AFTER EARNINGS: Identiv (INVE), down 10.3%... Sphere 3D (ANY), down 11.3%... VOXX International (VOXX), down 8.1%. ALSO LOWER: Puma Biotechnology (PBYI), down 21.8% after Neratinib data published in ASCO abstract... Karyopharm Therapeutics (KPTI), down 1.2% after ASCO presentation data released... Gevo (GEVO), down 11.4% after filing to sell common stock and warrants.
18:37 EDTKPTIBiopharmaceutical stocks volatile after release of ASCO presentation data
After the market close, the American Society of Clinical Oncology, or ASCO, provided public access to 5,000 cancer drug trial research abstracts ahead of the society's 51st annual meeting from May 29 to June 2 in Chicago, Illinois. In after-hours trading, a number of biopharmaceutical stocks were active, including Vascular Biogenics (VBLT) and Oncothyreon (ONTY), which rose 13% and 14.9%, respectively, and Puma Biotechnology (PBYI) and Karyopharm Therapeutics (KPTI), which fell 23.9% and 14.8%, respectively.
18:01 EDTKPTIKaryopharm down 14.8% after ASCO presentation data released
Subscribe for More Information
17:19 EDTKPTIKaryopharm to present 'encouraging' data on selinexor at 2015 ASCO meeting
Karyopharm Therapeutics announced that four abstracts describing the activity of selinexor, or KPT-330, the company's lead drug candidate in development for hematological malignancies and solid tumors, have been selected for presentation at the 2015 American Society of Clinical Oncology annual meeting, May 29 to June 2. The abstracts represent both company and investigator-sponsored clinical studies. Data to be presented include phase 2 clinical updates in both gynecologic cancers and recurrent glioblastoma, as well as phase 1b clinical data in advanced sarcomas and phase 1 clinical data in Asian patients with advanced solid and hematological cancers. "We are encouraged by the activity observed to date with selinexor in solid tumors, including the single-agent data to be presented at ASCO demonstrating durable anti-cancer activity and disease control in excess of three months across a broad range of heavily pretreated tumor-types including ovarian and endometrial cancers and advanced sarcomas. We are also particularly excited about the clear demonstration of brain penetration and anti-tumor activity of single-agent selinexor in relapsed or refractory glioblastomas," said Sharon Shacham, Chief Scientific Officer of Karyopharm.
07:19 EDTVRTXVertex shares should have upward momentum in near-term, says JMP Securities
Subscribe for More Information
07:08 EDTZINCOppenheimer to hold a conference
Subscribe for More Information
06:29 EDTZBRAZebra Technologies sees Q2 EPS $1.00-$1.25, consensus $1.17
Subscribe for More Information
06:28 EDTZBRAZebra Technologies reports Q1 EPS $1.39 consensus $1.12
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use